New combo therapy targets tough liver cancer cases
NCT ID NCT06349317
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study is for people with liver cancer that has spread into the main vein of the liver (portal vein tumor thrombus) and can still be removed by surgery. The goal is to see if giving a combination of radiation, an immunotherapy drug (camrelizumab), and a targeted therapy pill (apatinib) before and after surgery can help prevent the cancer from coming back. About 33 participants will receive this treatment and be followed for one year to measure how long they live without the cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mengchao Hepatobiliary Hospital, Fujian Medical University
RECRUITINGFuzhou, Fujian, China
Contact
Conditions
Explore the condition pages connected to this study.